# Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

> **NCT01261741** · PHASE2 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 299 (actual)

## Conditions studied

- Memory Disorder
- Retention Disorder, Cognitive
- Subjective Cognitive Impairment
- Memory, Concentration or Attention Problems

## Interventions

- **DRUG:** Memantine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01261741
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-09
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2013-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261741, "Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01261741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*